


MODAPLEX Copy Number High Analysis Kit

Analyse copy number variations within endometrial cancer



FEATURES OF THE COH ANALYSIS

- Detect copy number variations using 6 reference regions and 8 target regions enabling TCGA classification
- Tested with gDNA derived from 100 endometrial cancer FFPE samples
- Experience the advantages of a thorough control strategy that ensures a high level of accuracy

AN IMPROVED TESTING WORKFLOW

- Fast and easy workflow with a 4 h turnaround time
- Use the intuitive MODAPLEX Reporter software for a simple and fast data analysis experience
- Test the recommended markers of the TCGA classification in one run




POWERFUL MODAPLEX PLATFORM

- High multiplexing grade in a single well
- Universal PCR program for running all three assays on one plate simultaneously
- The MODAPLEX setup is as straightforward as setting up a PCR
- Simple analysis with the intuitive MODAPLEX Reporter software

Identify copy number high positive endometrial cancers according to the TCGA classification

An integrated genomic characterization of endometrial cancer was performed by The Cancer Genome Atlas Research Network (TCGA), which identified four distinct molecular subgroup⁽¹⁾. The prognostic information of this classification was confirmed by two groups in 2015/2016 and applied in the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) using immunohistochemistry of P53 as a surrogate marker for the high copy number group^(2, 3, 4). This adapted molecular classification has now been incorporated into endometrial carcinoma guidelines, published by the European Society of Gynaecological Oncology (ESGO), the European Society of Pathology (ESP) and ESMO^(5,6).



Adapted from Levine et al (7) 10.1038/nature12113

Due to cost and time constraints, modern pathology is increasingly shifting towards molecular analyses. While the informativeness of IHC samples heavily relies on fixation and staining conditions, DNA-based methods are robust, especially when directly extracted from tissue.

BIOTYPE's Copy Number High assay enables the user to classify samples into the copy number high group by semi-quantitatively comparing regions with a very low likelihood of copy number variations (reference regions) to regions exhibiting a very high likelihood of copy number variations (target regions).

REFERENCES:

- 1 Kandath et al., Integrated genomic characterization of endometrial carcinoma. *Nature* 497, 67–73 (2013).
- 2 Talhouk et al., A clinically applicable molecular-based classification for endometrial cancers. *Br. J. Cancer* 113, 299–310 (2015).
- 3 Stelloo et al., Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts. *Clinical cancer research* 22, 4215–4224 (2016).
- 4 Talhouk et al., Confirmation of ProMisE. *Cancer* 123, 802–813 (2017).
- 5 Concin et al., ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. *Int. J. Gynecol. Cancer* 31, 12–39 (2021)
- 6 Oaknin et al., Endometrial cancer. *Ann. Oncol.* 33, 860–877 (2022).
- 7 Levine et al., The Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. *Nature* 497, 67–73 (2013).

ORDER INFORMATION

Product	Size	Cat. No.	Status
MODAPLEX Copy Number High Analysis Kit	50 reactions	85-15001-0050	RUO*

*RUO - Research Use Only products must be validated by the customer with clinically relevant material for diagnostic purposes.

Direct your orders via email to sales@biotype.de